June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
IL-18 promotes wound healing and has anti-angiogenic properties in the eye
Author Affiliations & Notes
  • Sarah Doyle
    Clinical Medicine, Trinity College Dublin, Dublin 2, Ireland
    National Children's Research Centre, Our Lady's Children's Hospital, Dublin, Ireland
  • Peter S Adamson
    Ophthalmology, Discovery Performance Unit, GSK, Stevenage, United Kingdom
  • Francisco J Lopez
    Ophthalmology, Discovery Performance Unit, GSK, King of Prussia, PA
  • Peter Humphries
    Ocular Genetics Unit, Trinity College Dublin, Dublin, Ireland
  • Matthew Campbell
    Ocular Genetics Unit, Trinity College Dublin, Dublin, Ireland
  • Footnotes
    Commercial Relationships Sarah Doyle, GSK (F), Use of IL-18 for neovascular AMD: European Patent Application No. 12772743.6. (P); Peter Adamson, GSK (E); Francisco Lopez, GSK (E); Peter Humphries, Use of IL-18 for neovascular AMD (P); Matthew Campbell, GSK (F), Use of IL-18 for neovascular AMD (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2462. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah Doyle, Peter S Adamson, Francisco J Lopez, Peter Humphries, Matthew Campbell; IL-18 promotes wound healing and has anti-angiogenic properties in the eye. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2462.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Age-related macular degeneration (AMD) is the leading cause of central vision loss in the developed world. Although choroidal neovascularization (CNV) is the less common end stage of disease, it accounts for ~90% of blindness caused by the disease. We live in an aging society witnessing a steady rise in obesity. This obesity epidemic is contributing to increasing incidence of diabetes. Diabetic retinopathy (DR) is the primary cause of vision loss in people of working age with 99% of Insulin-dependent diabetics affected within 20 years. Current anti-VEGF (Vascular endothelial growth factor) therapies have revolutionized treatment for ‘neovascular’ AMD and DR and directly implicate VEGF as a key regulator of pathological vasopermeability and angiogenesis. However, the importance of VEGF’s role as a neuronal survival factor cannot be overlooked, underscored by the observation that in patients receiving long-term anti-VEGF therapy the neural retina can begin to degenerate resulting in further vision loss. For this reason tailoring therapies to attenuate specific signal transduction cascades, reducing the side effects of “anti-VEGF” treatment holds significant therapeutic promise.<br /> We discovered that IL-18 controls CNV formation in mice with no effect on retinal pigment epithelial (RPE) cell viability at therapeutic doses. The potential use of recombinant IL-18 as an immunotherapy is proving itself safe and efficacious at every step, however, its use as a direct immunotherapy remains controversial. Therefore, it is imperative that we map out the signaling cascades initiated in response to IL-18 that result in the anti-angiogenic and anti-permeability phenotype.

Methods: Primary human retinal microvascular endothelial cells and RPE cells were treated with various doses of IL-18, VEGF or both, over time and assayed by qPCR, Western Blot and ELISA.

Results: Compellingly, our studies have indicated that IL-18 specifically inhibits the VEGF/VEGFR2 signaling axis. VEGFR2 signaling appears to be mainly involved in promoting vascular permeability and angiogenesis, whereas VEGFR1 promotes cell survival, therefore designing therapies that block VEGFR2 signaling specifically would have the most impact.

Conclusions: Our data indicates that the signal transduction pathways elicited by IL-18 hold within them the key to the rational design of a new generation of tailored anti-angiogenesis therapies.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.